Top Story
Real World EvidenceThe global Real World Evidence (RWE) Solutions Market is projected to grow substantially, from USD 43.22 billion in 2022 to USD 78.83 billion by 2030, with a Compound Annual Growth Rate (CAGR) of 7.8%. This growth is driven by the rising adoption of RWE solutions in [...]
Latest Stories
Featured Webinars
Practical AI: Adding Insight to the Patient Journey with Digital Phenotyping
Thursday, May 23, 2024
Sponsor: OM1
Insights from the 2024 Salary Survey Report by HealthEconomics.com
Wednesday, May 1, 2024
Webinar Host: Scientist.com
Beyond Accelerated Approvals: External Control Arms
Wednesday, April 10, 2024
Sponsor: Cardinal Health
Delphi Panels: What Are They Good For?
Tuesday, March 12, 2024
Sponsor: Partnership for Health Analytic Research (PHAR)
Handpicked Promotions & Highlights
Latest in Catalyst News powered by BioPharmCatalyst
05/01/2024 04:45 PM ET
FibroBiologics FDMT date announcement
4D Molecular Therapeutics already had eight catalyst announcements coming up, but they added another one today. It will be announcing top-line results for their recent Phase 1/2 trial for 4D-150 - (PRISM) on September 30, [...]
Read More
05/01/2024 04:45 PM ET
KalVista Pharmaceuticals KALV results announcement
KalVista Pharmaceuticals provided an update to their Phase 1 trial for Sebetralstat - (KONFIDENT-KID). The results were summarized as follows:
"Trial planned for 3Q 2024."
KalVista Pharmaceuticals rocketed up $0.83 (+7.31%) to $12.18 on light [...]
Read More
05/01/2024 04:45 PM ET
Minerva Neurosciences NERV earnings announcement
Minerva Neurosciences revealed their most recent quarterly earnings data, in which EPS ended up higher than estimates. EPS was reported to be -$1.13, which beat the estimated value of -$1.20. Minerva Neurosciences' EPS [...]
Read More
05/01/2024 04:45 PM ET
BioAtla SMMT earnings announcement
Summit Therapeutics revealed their most recent quarterly earnings data for Q1. EPS was reported to be -$0.06. It is now above its average of -$0.32 over the past year.
Investors were clearly happy with [...]
Read MoreSearch HealthEconomics.com
Throw in a keyword, research topic, disease model or technology of interest
